Suppression of total digoxin concentrations by digoxin-like immunoreactive substances in the MEIA digoxin assay: Elimination of negative interference by monitoring free digoxin concentrations

American Journal of Clinical Pathology

Volumn 111, Issue 3, 1999, Pages 406-410

  Dasgupta, Amitava ^a   Trejo, Octavio ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Digoxin; Digoxin like immunoreactive substances; DLIS; Free digoxin; MEIA; Microparticle enzyme immunoassay

Indexed keywords

DIGITALIS LIKE FACTOR;

ARTICLE; CROSS REACTION; DRUG DETERMINATION; DRUG MONITORING; ENZYME IMMUNOASSAY; FLUORESCENCE POLARIZATION IMMUNOASSAY; PRIORITY JOURNAL; UREMIA;

EID: 0033029719     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/111.3.406     Document Type: Article

References (17)

1. Graves SW, Brown BA, Valdes R. Digoxin-like immunoreactive substances in a patient with renal impairment. Ann Intern Med. 1983;99:604-608.
2. Nanja AA, Greenway DC. Falsely raised plasma digoxin concentrations in liver disease. BMJ. 1985;290:432-435.
3. Sault MH, Vasdev SC, Longerich LL. Endogenous digoxin-like substances in patients with combined hepatic and renal failure. Ann Intern Med. 1984;58:748-751.
4. Graves SW. The possible role of digitalis-like factors in pregnancy induced hypertension. Hypertension. 1987;10(suppl I):184-186.
5. Cloix JF. Endogenous digitalis like compounds. Hypertension. 1987;10(suppl I):67-70.
6. Shilo L, Adwani A, Solomon G, et al. Endogenous digoxin-like immunoreactivity in congestive heart failure. BMJ. 1987;295:415-416.
7. Ahmad S, Kenny M, Scribner BH. Hypertension and a digoxin-like substance in the plasma of dialysis patients: possible marker for a natriuretic hormone. Clin Physiol Biochem. 1986;4:210-216.
8. Soldin SJ. Digoxin issues and controversies. Clin Chem. 1986;32:5-12.
9. Stone JA, Soldin SJ. An update on digoxin. Clin Chem. 1989;35:1326-1331.
10. Crossey MJ, Dasgupta A. Effects of digoxin like immunoreactive substances and digoxin FAB antibodies on the new digoxin microparticle enzyme immunoassay. Ther Drug Monit. 1997;19:185-190.
11. Miller JJ, Straub RW, Valdes R. Analytical performance of a monoclonal digoxin assay with increased specificity on the ACS: 180. Ther Drug Monit. 1996;18:65-72.
12. Smith TW. Digitalis toxicity: epidemiology and clinical use of serum concentration measurements. Am J Med. 1975;58:470-476.
13. Smith TW, Haber E. Digoxin intoxication: the relationship of clinical presentation to serum digoxin concentration. J Clin Invest. 1970;49:2377-2386.
14. Valdes R, Graves SW. Protein binding of endogenous digoxin-like immunoreactive factor in human serum and its variation with clinical condition. J Clin Endocrinol Metab. 1985;60:1135-1143.
15. Miller JJ, Valdes R. Methods for calculating cross reactivity in immunoassays. J Clin Immunoassay. 1992;15:97-100.
16. Jortani SA, Miller JJ, Helm RA, et al. Unexpected suppression of digoxin values caused by DLIF [abstract]. Clin Chem. 1996;42:S124.
17. Dasgupta A, Schammel D, Limmany A, et al. Estimating concentration of total digoxin and digoxin-like immunoreactive substances in volume expanded patients being treated with digoxin. Ther Drug Monit. 1996;18:34-39.